
About Lavue Pharmaceuticals Private Limited
Data last updated:
Lavue Pharmaceuticals Private Limited is a private limited company based in Mumbai, Maharashtra, India, a subsidiary of Acumedica Consulting Private Limited. It operates in the eye care and ophthalmology clinics segment of the healthcare sector. It was incorporated on 30 September 2009 and has been in existence for over 17 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U74900MH2009PTC196131. Its GSTIN is 27AAACQ2032R3Z5 (Maharashtra). The company holds 3 GST registrations, of which 2 are active.
The company has an authorised share capital of ₹11.14 Cr and a paid-up capital of ₹11.14 Cr. It was formerly known as Q-Rexa Pharmaceuticals Private Limited. It is led by directors including Sameer Ashok Paigankar and Darshak Jitendra Shah.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Unit Number 109 First Floor Kanakia Zillion Lbs Road BKC Annexure Kurla (West), Mumbai, Maharashtra, India – 400070.
As per the financials filed for FY 2025, the company reported a revenue of ₹20.77 Cr, a growth of 60% compared to the previous year. For the same year it recorded a net loss of ₹2.02 Cr (net margin -9.7%) and EBITDA of -₹2.7 Cr (EBITDA margin -13%). Revenue has grown at a compounded annual rate (CAGR) of 47% over three years and 37% over five years.
The company has about 98 employees on its provident fund (EPFO) records.
The company has 8 deals on record (5 convertible or debt financings, 2 secondary share transfers, 1 rights issue), with disclosed funding of ₹14.61 Cr; the latest was in June 2021. Its 3 peer companies in the Healthcare industry (Eye Care, Pharmaceuticals), with the same principal business activity (wholesale trading) are compared by revenue, 1 larger and 2 smaller; the largest is Dr. Acharya Pharmaceuticals Private Limited with revenue of ₹21.44 Cr. The company has 9 MSME Form 1 returns on record between 2019 and 2023, listing 246 overdue payments to 9 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website lavue.co.in.
Company details
Contact details
Lavue Pharmaceuticals Private Limited's registered office is in Mumbai, Maharashtra. Its website is lavue.co.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressUnit Number 109 First Floor Kanakia Zillion Lbs Road BKC Annexure Kurla (West), Mumbai, Maharashtra, India – 400070
- IndustryHealthcare, Eye Care & Ophthalmology Clinics
To see the full contact details of Lavue Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Lavue Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Lavue Pharmaceuticals Private Limited, buy the company report.
Financials of Lavue Pharmaceuticals Private Limited
FY 2025 filings availableLavue Pharmaceuticals Private Limited reported revenue of ₹20.77 Cr (up 60% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 37% over five years, including 60% growth in the latest year. EBITDA rose 18% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹2.7 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹2.02 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -13% | ||||
| Net Profit Margin | -9.7% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Lavue Pharmaceuticals Private Limited, buy the company report.
Board of directors of Lavue Pharmaceuticals Private Limited
Lavue Pharmaceuticals has 3 current directors and 1 former director. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sameer Ashok Paigankar Also directs: Pharma-Serv Healthcare Private Limited, Pharma Serv Ventures Private Limited, Nutragenix Healthcare Private Limited and 4 more | Director | 30 Sep 2009 | 17 Years 1 Months | Current |
| Darshak Jitendra Shah | Director | 21 Dec 2009 | 16 Years 10 Months | Current |
| Murali Venkata Krishna Sistla | Director | 21 Dec 2009 | 16 Years 10 Months | Current |
Peer comparison
Lavue Pharmaceuticals Private Limited is compared with the 3 companies closest to it by revenue in the Healthcare industry (Eye Care, Pharmaceuticals), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Dr. Acharya Pharmaceuticals Private Limited | ₹21.44 Cr (FY 2025) | 15.0% | Bhubaneswar, Odisha, India | |||
| Lavue Pharmaceuticals Private Limitedthis company | ₹20.77 Cr (FY 2025) | -₹2.02 Cr | -9.7% | 60.0% | 98 | Mumbai, Maharashtra, India |
| Essel Pharmaceuticals Private Limited | ₹20.71 Cr (FY 2025) | 130.0% | Kanpur, Uttar Pradesh, India | |||
| Bhattacharjee Pharmaceuticals and Company Ltd | ₹20.61 Cr (FY 2024) | 13.0% | Beleghata, West Bengal, India |
To see the full peer comparison of Lavue Pharmaceuticals Private Limited, buy the company report.
Auditor
Lavue Pharmaceuticals Private Limited is audited by PHD & Associates for the financial year 2021.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| PHD & Associates | FY 2021 | 111236W |
Shareholding
The shareholding of Lavue Pharmaceuticals Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Lavue Pharmaceuticals Private Limited, buy the company report.
Deals & funding
Lavue Pharmaceuticals Private Limited has 8 deals on record (5 convertible or debt financings, 2 secondary share transfers, 1 rights issue), with disclosed funding of ₹14.61 Cr; the latest was in June 2021.
Deals on record (3 of 8)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Aug 2017 | Rights issue | ₹10 Lakh | Investors: Acumedica Consulting Private Limited , Eyeskape Medicals Private Limited , Pharma Serv Ventures Private Limited |
| Jul 2017 | Secondary share transfer | Undisclosed | Buyer: Pharma Serv Ventures Private Limited , Eyeskape Medicals Private Limited , Acumedica Consulting Private Limited Seller: Pharma Serv Solutions Private Limited & Sistla Venkata Krishna Murli, Pharma Serv Solutions Private Limited, Pharma Serv Solutions Private Limited & Darshak Jitendra Shah |
| Dec 2009 | Secondary share transfer | Undisclosed | Buyer: Pharma Serv Solutions Private Limited & Sameer A Paigankar, Pharma Serv Solutions Private Limited & Darshak Jitendra Shah, Pharma Serv Solutions Private Limited Seller: 2 individuals |
To see the full deal history of Lavue Pharmaceuticals Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Lavue Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
Lavue Pharmaceuticals Private Limited has 9 MSME Form 1 returns on record between 2019 and 2023, listing 246 overdue payments to 9 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 9)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Shreeair Cargo Private Limited | |||
| Solistaa Pharmaceuticals Private Limited | |||
| an individual supplier | |||
| D K Enterprises | |||
| an individual supplier |
To see the full MSME payment records of Lavue Pharmaceuticals Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Lavue Pharmaceuticals Private Limited has a workforce of 98 employees on its EPFO records as of Apr 09, 2024, across 1 active EPFO establishment.
GST
Lavue Pharmaceuticals has 3 GST registrations: 2 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACQ2032R3Z5 | Maharashtra | Active | 01 Jul 2017 |
| 06AAACQ2032R1ZB | Haryana | Active | 12 Aug 2022 |
To see the full GST registrations and return filing status of Lavue Pharmaceuticals Private Limited, buy the company report.
Recent activity
Lavue Pharmaceuticals Private Limited has 4 board changes on record since 2009: 3 appointments and 1 cessation. The latest: Sheela Sameer Paigankar ceased to be Director on 05 Mar 2010.
Frequently asked questions
Lavue Pharmaceuticals is an active private limited company based in Mumbai, Maharashtra, India. The company works in eye care and ophthalmology clinics, within the healthcare industry. It was incorporated on 30 September 2009 (17+ years old) and is registered under CIN U74900MH2009PTC196131.
Lavue Pharmaceuticals has 3 current directors:
- Sameer Ashok Paigankar - Director
- Darshak Jitendra Shah - Director
- Murali Venkata Krishna Sistla - Director
The latest financial statements of Lavue Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Lavue Pharmaceuticals is 27AAACQ2032R3Z5, registered in Maharashtra. The company has 3 GST registrations in all, of which 2 are active and 1 is cancelled or inactive. Other active GSTINs include 06AAACQ2032R1ZB (Haryana).
The CIN (Corporate Identification Number) of Lavue Pharmaceuticals is U74900MH2009PTC196131. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Lavue Pharmaceuticals was incorporated on 30 September 2009, making it 17+ years old. It is registered with the Registrar of Companies, Mumbai.
Lavue Pharmaceuticals has 8 deals on record (5 convertible or debt financings, 2 secondary share transfers, 1 rights issue), with disclosed funding of ₹14.61 Cr; the latest was in June 2021.
The peers of Lavue Pharmaceuticals by revenue are Dr. Acharya Pharmaceuticals Private Limited, Essel Pharmaceuticals Private Limited, Bhattacharjee Pharmaceuticals and Company Ltd, all in the Healthcare industry (Eye Care, Pharmaceuticals), with the same principal business activity (wholesale trading).
Sheela Sameer Paigankar ceased to be Director on 05 Mar 2010. Darshak Jitendra Shah was appointed as Director on 21 Dec 2009. Murali Venkata Krishna Sistla was appointed as Director on 21 Dec 2009. Lavue Pharmaceuticals has 4 board changes on record in total.
Lavue Pharmaceuticals has 9 MSME Form 1 returns on record between 2019 and 2023, listing 246 overdue payments to 9 micro and small suppliers. The latest return was filed on 04 Sep 2023.
Lavue Pharmaceuticals can be reached through the website lavue.co.in. Its registered office is in Mumbai, Maharashtra, India.
The registered office of Lavue Pharmaceuticals is at Unit Number 109 First Floor Kanakia Zillion Lbs Road BKC Annexure Kurla West, Mumbai, Maharashtra, India – 400070.

